Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.

Authors

Lee M Greenberger¹, Larry A Saltzman², Jonathon W Senefeld³, Patrick W Johnson⁴, Louis J DeGennaro², Gwen L Nichols²

Affiliations

¹ The Leukemia & Lymphoma Society, Rye Brook, NY, USA. Electronic address: lee.greenberger@lls.org.
² The Leukemia & Lymphoma Society, Rye Brook, NY, USA.
³ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibody Formation
COVID-19 Vaccines
COVID-19*
Hematologic Neoplasms* / therapy
Humans
SARS-CoV-2

Substances

COVID-19 Vaccines